Drug intelligence / Profile preview

BIBX-245

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BIBX-245 is a small molecule drug developed by Boehringer Ingelheim International GmbH. It acts as an inhibitor of lanosterol synthase (OSC), an enzyme involved in cholesterol biosynthesis. By inhibiting OSC, BIBX-245 was investigated for its potential to lower cholesterol levels, specifically targeting hypercholesterolemia. The drug reached Phase 1 clinical trials, where its pharmacokinetics and the effect of food on its absorption were studied in healthy subjects[1].

Other names: BIBX 245BIBX245BIBX-245

Targets

LSS (Lanosterol synthase)

Beyond the preview

Go deeper on BIBX-245.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIBX-245.

Explore the full profile